Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP-001 in High-Risk Acute Graft Versus Host Disease
NCT05643638Phase 2Terminated
- Sponsor
- Cynata Therapeutics
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 7
01
Overview
A Phase 2 trial of Cymerus MSCs in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Cynata Therapeutics. Started Mar 2024; status: terminated.
02
Drugs
Cymerus MSCs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT05643638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05643638.